The anticoagulation therapy for pulmonary embolism is divided into the following three aspects: First, the anticoagulation therapy of heparin in the past was carried out by intravenous drip or injection, which needs to be adjusted by testing coagulation sign and ACT during application, and heparin application may produce complications such as thrombocytopenia. In the second aspect, low molecular heparin comes for subcutaneous injection and the dose is set according to the patient’s weight, usually every 12 hours. Low-molecular heparin application may also produce complications such as thrombocytopenia. The third aspect is oral anticoagulant therapy, including warfarin and rivaroxaban, etc. Since warfarin requires monitoring of coagulation images, new anticoagulant therapy represented by rivaroxaban is now mostly used clinically once a day, with relatively clear effects and relatively low risk of bleeding. Regardless of which anticoagulation therapy is used, it should be monitored regularly to avoid the risk of bleeding.